TEL-AVIV, Israel, June 27, 2011 /PRNewswire/ —
InspireMD, Inc. (OTC BB: NSPR) (“Inspire” or the “Company”),
the developer of the MGuard™ mesh protective stent system,
today announced it has signed a distribution agreement with
IMPLANTA, a well-established Moscow-based supplier to medical
centers throughout the Russian Federation.
Under terms of the agreement, ZAO Implanta will work to use its
distribution network in the Russian Federation for the sale of
InspireMD’s MGuard™ coronary stent systems. ZAO Implanta is
one of the major medical instrumentations and stent distributors in
the Russian Federation and has representative offices in various
regions and cities, including Vladivostok, Nizhny Novgorod, St.
Petersburg, Samara, Yekaterinburg, Novosibirsk and Krasnodar.
MGuard was launched at the 13th Moscow International Course on
Vascular Diagnosis and Treatment of Congenital and Acquired Heart
Diseases in Bakulev, Moscow. The Bakulev Scientific Center of
Cardiovascular Surgery is one of the
leading cardiovascular surgery-related facilities of
the Russian Federation.
Sara Alon-Paz, Vice President of Sales of InspireMD commented,
“As we continue to validate our technology, including the
randomized trial currently underway, we are simultaneously building
a world-class distribution network to position us to capture market
share in the future. Adding a proven distributor like ZAO Implanta,
with more than a dozen years in the market and a reputation for
distributing the newest medical technologies, is in-line with our
vision. We are excited about the potential in the Russian
Federation market, and look forward to penetrating this growing
region’s market as we complete validation studies.”
“IMPLANTA has a history of selecting the newest, unique
and most advanced, technologies for distribution and we are excited
to continue this by adding MGuard to our portfolio,”
commented Mr. Petr A. Gukovskiy,
‘/>”/>
